CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the nam
Related Questions
How will the merger affect Vyome Therapeutics' and ReShape Lifesciences' combined market valuation?
Will there be any share issuance or dilution for existing shareholders as a result of the merger?
Will the merger trigger any changes in institutional ownership or analyst coverage?
What is the expected impact of the Nasdaq listing under the new ticker HIND on liquidity and trading volume?
What synergies and cost savings are projected from the integration of Vyome and ReShape?
How does the combined company's pipeline compare to competitors in the immuno‑inflammatory and rare disease space?
What are the key milestones and timelines for product development post‑merger?
How might the market react to the re‑branding and new ticker on the first day of trading (August 15, 2025)?
Are there any regulatory or FDA considerations that could delay or impact the merger’s completion?
What is the anticipated impact on earnings per share (EPS) and revenue growth forecasts for the combined entity?